| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | — |
| Gross profit | -1.0 | — |
| Net income | -5.8 | -3.6 |
| EPS (diluted, $ a share) | $-0.09 | $-0.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MBOT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Microbot Medical Inc.: key numbers
- Share price
- $0.6444Close, Nov 16
- Market cap
- $43.3M
- Shares outstanding
- 67.16MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Microbot Medical Inc.
All →Microbot Medical Business Update
Microbot Medical provided a third quarter 2026 operational update highlighting a 44% sequential increase in procedure utilization for its LIBERTY Endovascular Robotic System. The company ended the quarter with $62 million in cash and expanded its commercial footprint to 12 customer accounts and 10 sales territories.
Microbot Medical Business Update
Microbot Medical announced that the Canadian Intellectual Property Office granted a patent for an adaptor used in its LIBERTY Endovascular Robotic System. This grant brings the company's global intellectual property portfolio to 45 issued patents and 48 pending applications, supporting its strategy for international commercialization expansion.
- Counterparty
- Canadian Intellectual Property Office
Microbot Medical Wins Contract from Elmnt Ir
Microbot Medical secured its first Office-Based Laboratory (OBL) customer, ELMNT IR, which signed an order for up to a 12-month supply of the LIBERTY Endovascular Robotic System. This marks the company's first customer on the U.S. West Coast and supports its strategy to expand into outpatient interventional radiology settings.
- Counterparty
- ELMNT IR
- Term
- 12 months
Microbot Medical Business Update
Microbot Medical announced its attendance at the SIR EDGE 2026 conference and the ACIR Annual Fall Conference to engage with interventional radiologists and hospital administrators. The company aims to leverage these events to generate sales leads and foster adoption of its FDA-cleared LIBERTY Endovascular Robotic System as it expands its U.S. commercial footprint.
Microbot Medical Business Update
Microbot Medical announced it has received several new patent approvals for its LIBERTY Endovascular Robotic System in the U.S., Japan, China, and Canada. The company's global intellectual property portfolio now includes 44 issued patents and 49 pending applications as it pursues commercial expansion and a CE Mark for international markets.
Microbot Medical Wins Contract from Medtechnica Ltd.
Microbot Medical Inc. entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System in Israel. The company expects initial orders under the agreement to begin in the fourth quarter of 2026 following prior regulatory approval from the Israeli Ministry of Health.
- Counterparty
- Medtechnica Ltd.
- Term
- 3 years